Movement Alert|DexCom Falls 5.09% in Regular Trading, Prior Earnings-Driven Gains Continue to Unwind

Market Focus11-07

On November 7, DexCom fell 5.09% in Regular Trading, trading at $80.21, with turnover of $92.48 million.

The most relevant recent catalyst in public information is that the stock had rallied after stronger-than-expected third-quarter results and a higher full-year revenue outlook, and the current move indicates that those post-earnings gains are continuing to unwind.

DexCom previously reported third-quarter adjusted EPS of $0.73, above the $0.67 consensus, on revenue of $1.344 billion, ahead of the $1.327 billion expectation. The company also raised its full-year revenue guidance to $5.20 billion-$5.25 billion from $5.18 billion-$5.25 billion. A later analyst note said the results and guidance pointed to stronger momentum into next year, supported by U.S. share gains, near-record global new-patient additions, and ongoing conversion to the 15-day G7 sensor.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment